Alessandro Vatrella
Prof Alessandro Vatrella, MD, Fers is an expert in Pulmonology at University of Salerno (Italy). As of October 2026, ScienceLeadR ranks Alessandro Vatrella in the top 1% of experts worldwide for Asthma, Hypersensitivity and Lung Diseases, Obstructive. Alessandro Vatrella has authored 207 publications, the most recent in 2026, and is an investigator in 4 clinical trials, 3 of them ongoing. SLR score: 634 (community average: 125). How the SLR is computed.
LeadR Profile
Pulmonology
Subspecialties: Immunology - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1996 - 2026
Number : 207
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Geriatric respiratory medicine 2026: from artificial intelligence to personalised management of the multimorbid patient. PMID 42906940 — pulmonary medicine, intelligence, lung, respiratory tract diseases, therapeutics, artificial intelligence | Eur Respir Rev | 2026 | 0 |
| Biologic Use in Type 2 versus Non-Type 2 Asthma: Similarities, Differences, and Challenges. PMID 42899165 — antibodies, adrenal cortex hormones, biomarkers, antibodies, monoclonal, therapeutics, asthma | J Inflamm Res | 2026 | 0 |
| Benralizumab in Severe Eosinophilic Asthma: Toward Disease Control and Evolving Treatment Paradigms. PMID 42741441 — lung, adrenal cortex hormones, eosinophils, therapeutics, asthma, biological therapy | J Inflamm Res | 2026 | 0 |
| Unburdening healthcare systems through telenursing in chronic respiratory disease management: a systematic review. PMID 42255281 — disease management, telenursing, hospitalization, treatment adherence and compliance, nursing, telemedicine, therapeutics, asthma, emergency service, hospital | Front Digit Health | 2026 | 0 |
| Impact of Single-Inhaler Triple Therapy FF/UMEC/VI on Disease Stability in COPD: A Real-World 12-Month Analysis. PMID 42234341 — lung, health status, signs and symptoms, pulmonary disease, chronic obstructive, therapeutics, vital capacity | Pulm Ther | 2026 | 0 |
Clinical Studies 4
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
3 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| An open label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma 2024-512113-41-00 — maintenance, therapeutics, asthma | Phase 3 | Active not recruiting | 2024 |
| A Study to Learn About the Study Medicine Called PF 07275315 in People With Moderate to Severe Asthma 2024-517866-40-00 — safety, asthma | Phase 2 | Recruiting | 2025 |
| MANI Real life Perspective Observatory NCT04796844 — cohort studies, asthma | N/A | Recruiting | 2021 |
LeadR Networks
Main global connection map